This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wirden, M.
Right arrow Articles by Calvez, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wirden, M.
Right arrow Articles by Calvez, V.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, June 2003, p. 2713-2715, Vol. 41, No. 6
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.6.2713-2715.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs

Marc Wirden,1 Anne Simon,2 Luminita Schneider,3 Roland Tubiana,3 Luc Paris,3 Anne Genevieve Marcelin,1 Constance Delaugerre,1 Mayeule Legrand,4 Serge Herson,2 Gilles Peytavin,5 Christine Katlama,3 and Vincent Calvez1*

Departments of Virology,1 Internal Medicine,2 Infectious Diseases,3 Pharmacology, Pitié-Salpêtrière Hospital,4 Department of Pharmacology, Bichat Hospital, Paris, France5

Received 5 November 2002/ Returned for modification 28 February 2003/ Accepted 7 March 2003

A 2-month interruption of only nonnucleoside reverse transcriptase inhibitors (NNRTIs) for patients carrying mutations associated with resistance to NNRTIs was followed by no change in either viral load or CD4 cell counts. These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases.

* Corresponding author. Mailing address: CERVI, Department of Virology, 83, Blvd. de l'Hôpital, 75013 Paris, France. Phone: 33142177401. Fax: 33142177411. E-mail: vincent.calvez{at}psl.ap-hop-paris.fr.

Journal of Clinical Microbiology, June 2003, p. 2713-2715, Vol. 41, No. 6
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.6.2713-2715.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Wirden, M., Simon, A., Schneider, L., Tubiana, R., Malet, I., Ait-Mohand, H., Peytavin, G., Katlama, C., Calvez, V., Marcelin, A.-G. (2009). Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J Antimicrob Chemother 64: 1087-1090 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»